May 20 |
PTC Therapeutics rallies 18% on EU authorization update for Translarna
|
May 20 |
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
|
May 20 |
PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna
|
May 20 |
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
|
May 20 |
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
|
May 14 |
PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
|
May 14 |
PTC Therapeutics wins FDA priority review for gene therapy
|
May 14 |
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
|
May 1 |
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
|
Apr 30 |
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
|